Lexaria Bioscience (LEXX) Liabilities and Shareholders Equity (2011 - 2026)

Lexaria Bioscience has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $6.5 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $6.5 million, down 25.24% year-over-year; the trailing twelve-month figure through Feb 2026 was $23.5 million (down 36.08% YoY), and the FY2025 annual result was $4.2 million, down 52.92% from the prior year.
• Liabilities and Shareholders Equity came in at $6.5 million for Q1 2026 at Lexaria Bioscience, up from $6.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $11.4 million in Q1 2022 to a low of $63573.0 in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $6.5 million (2026), against an average of $5.5 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 99.26% in 2023 and soared 13716.86% in 2024, its largest moves.
• Lexaria Bioscience's Liabilities and Shareholders Equity stood at $118096.0 in 2022, then gained by 12.3% to $132627.0 in 2023, then surged by 7284.45% to $9.8 million in 2024, then plunged by 38.22% to $6.1 million in 2025, then rose by 7.21% to $6.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $6.5 million (Q1 2026), $6.1 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.